期刊文献+

系统性红斑狼疮的生物制剂治疗进展 被引量:3

下载PDF
导出
作者 周春丽 郝飞
出处 《重庆医学》 CAS CSCD 北大核心 2009年第3期345-347,共3页 Chongqing medicine
  • 相关文献

参考文献18

  • 1谢家印,李毅,向德兵,肖华亮,王毅,余娴,罗唯,王东.3例美罗华鞘注治疗中枢神经系统非霍奇金淋巴瘤临床分析[J].重庆医学,2007,36(20):2059-2061. 被引量:6
  • 2Looney R J, Anolik J H, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus:a phase Ⅰ / Ⅱ dose-escalation trial of rituximab[J]. Arthri tis Rheum, 2004,50 (8) : 2580.
  • 3Leandro MJ, Cambridge G, Edwards JC, et al. B-cell de pletion in the treatment of patients with systemic lupus erythematosus : a longitudinal analysis of 24 patients[J]. Rheumatology, 2005,44 (12) : 1542.
  • 4Tokunaga M,Saito K,Kawabata D, et al. Efficacy of rituximab(anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system[J]. Ann Rheum Dis,2007,66(4) :470.
  • 5Sfikakis PP, Boletis JN, L ionaki S, et al. Remission of proliferative lupus nephritis followingB cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an openlabel trial[J]. Arthritis Rheum, 2005,52 : 501.
  • 6Leandro M J, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus[J].Arthritis Rheum, 2002,46 : 2673.
  • 7Looney R J, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus:a phase Ⅰ/Ⅱ dose-escalation trial of rituximab[J]. Arthritis Rheum, 2004,50:2580.
  • 8Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis[J]. Arthritis Rheum, 2003,48:719.
  • 9Kalunian KC,Davis JC Jr, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti CD154: a randomized, double-blind, placebo controlled trial [J]. Arthritis Rheum, 2002, 46(12):3251.
  • 10Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus[J]. Arch Dermatol, 2007, 143(7) :873.

二级参考文献10

  • 1胡毅,冯奉仪,石远凯,周立强,顾大中,王奇璐.原发性中枢神经系统淋巴瘤28例临床分析[J].中华肿瘤杂志,2004,26(6):375-378. 被引量:22
  • 2Hoang-Xuan K,Camilleri-Broct S,Soussain C. Recent ad vanccs in primary CNS lymphoma[J]. Curr Opin Oncol, 2004,16:601.
  • 3Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphoma: Targeting the leptomeninge al compartment[J]. Blood,2003,101:466.
  • 4Lai R, Rosenblum MK, DeAngelis I.M. Primary CNS lymphoma a whole-brain disease[J]. Neurology,2002, 59:1557.
  • 5Suwanwela N, Tantanatrakool B, Suwanwela NC. In tracranial lymphoma CT and MR findings[J]. J Med As soc Thai,2001,84(1):228.
  • 6Hegde U,Filie A,Lttle RF,et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphoma at risk for central nervous system involvement: the role of flow cy tometry versus cytology[J]. Blood, 2005,105 : 496.
  • 7Lachance DH,O'Neill BP,Macdonald DR,et al. Primary leptomeningal lymphoma report of 9 cases diagnosis with immunocytochemical analysis and review of the literature [J]. Neurology,1991,41:95.
  • 8Fine HA, Mayer RJ. Primary central nervous system lymphoma[J]. Ann Intern Med,1993,119:1093.
  • 9Schulz H, Pels H, Schmidt Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab[J]. Haematologi cal,2004,89(6) :753.
  • 10Antonini G,Cox MC, Montefusco E,et al. Intrathecal anti-CD20 antibody: An effective and safe treatment for leptomeningeal lymphoma[J]. J Neurooncol, 2006,(Springer 1):112.

共引文献5

同被引文献45

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部